Chief Business and Strategy Officer,
Global Blood Therapeutics
Location: San Francisco Bay Area
Member Since: 2017
Jung Choi serves as chief business and strategy officer for Global Blood Therapeutics (GBT), and is responsible for corporate development, strategy, patient advocacy, and government affairs. During her career, Ms. Choi has led or managed over 50 transactions exceeding $13 billion in value. Prior to GBT, she served as senior vice president, corporate development for InterMune, Inc., a biotechnology company acquired by Roche Holding AG, and as senior vice president, corporate development for Chimerix. She previously held various management positions at Gilead Sciences, Inc., including leadership of business development, licensing and mergers and acquisition activities. During her tenure at Gilead, she built and oversaw the corporate development group and led the U.S. commercial launch of Hepsera® for the treatment of hepatitis B virus. She also has venture capital and strategy experience having served as a vice president at Bay City Capital and an engagement manager at McKinsey & Company. Ms. Choi received a B.A. in human biology and an M.B.A. from Stanford University.